Reducing Risk Of Recurrence And A Stabilization In Incidence Of Renal Cell Carcinoma Will Limit Growth Of Drug-Treatment Opportunities
Projected improvements in recurrence-free survival and a discontinuation of the historically observed increases in the incidence rate of renal cell carcinoma (RCC) will limit growth of new drug-treatment opportunities for advanced disease in RCC.
The Cancer Nutrition Rehabilitation (cnr) program at the McGill University Health Centre is an interdisciplinary 8-week treatment program offering patients information, education, treatment, and support in areas such as diet, exercise, and rehabilitation, plus resources to address their psychosocial needs.
One of the tragi-comic sideshows of passing ObamaCare was the Democratic attempt to buy off the American Medical Association . . .
Axitinib significantly extended progression-free survival
"These data, in addition to positive tivozanib Phase 2 monotherapy data in patients with advanced kidney cancer, indicate significant potential for tivozanib across multiple tumor types.
If the Centers for Medicare and Medicaid Service and the Food and Drug Administration and god knows what other panels lurking in the lost crevices of our sprawling government decide to block access to Provenge, if they block Avastin, if they block Sutent, who will spend the billions necessary to research, develop, and bring new drugs to market?
To have the best chance of quitting successfully, you need to know what you're up against, what your options are, and where to go for help.